Scholarlink

<p>Post-transplant cyclophosphamide (PTCy) is standard in T cell-replete haploidentical transplants, but its use in matched sibling (MSD) and unrelated donor (MUD) HSCT remains limited, where CNI-MTx ± ATG regimens are still common. Real-world outcome data in matched donor settings, especially from India, are scarce. We retrospectively analysed 48 patients who underwent HSCT between 2018 and 2025. Patients were grouped based on GVHD prophylaxis: CNI/MTx (<i>n</i> = 35) and PTCy (<i>n</i> = 13). All patients were either matched sibling donors (MSD) or MUD. Engraftment, GVHD, CMV reactivations, relapse, survival outcomes, and complications were assessed using SPSS v25. A total of 48 patients (CNI/MTx: 35; PTCy: 13) were analysed. Baseline characteristics, including age, donor type, and diagnosis distribution, were comparable between groups. Acute GVHD occurred in 25.7% vs. 7.7% and chronic GVHD in 42.8% vs. 38.5% of patients, respectively. The mean RFS was 37.1 ± 4.6 vs. 26.1 ± 4.0 months, with median RFS not reached. The 12, 18, and 24 months RFS were 60.0%, 60.0%, and 60.0% for CNI/MTx and 72.5%, 60.4%, and 60.4% for PTCy. There was no significant difference. PTCy-based GVHD prophylaxis appears to be effective and well-tolerated in matched donor HSCT, with low rates of GVHD and transplant-related mortality. Further randomized trials comparing PTCy with CNI + MTx are needed to confirm these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Post-transplant Cyclophosphamide (PTCY) Based GVHD Prophylaxis in Matched Hematopoietic Stem Cell Transplant: A Retrospective Study

  • 期刊论文

  • 发表日期：

    2025年11月26日

查看全文
  • Nitin Gupta,
  • Meena Verma,
  • Deepika Gupta,
  • Naveen Vairamoorthy,
  • Saikat Mondal,
  • Naman Bansal,
  • Navneet Mishra,
  • Priyamvadha Ramesh,
  • Shruti Sinha

摘要

Post-transplant cyclophosphamide (PTCy) is standard in T cell-replete haploidentical transplants, but its use in matched sibling (MSD) and unrelated donor (MUD) HSCT remains limited, where CNI-MTx ± ATG regimens are still common. Real-world outcome data in matched donor settings, especially from India, are scarce. We retrospectively analysed 48 patients who underwent HSCT between 2018 and 2025. Patients were grouped based on GVHD prophylaxis: CNI/MTx (n = 35) and PTCy (n = 13). All patients were either matched sibling donors (MSD) or MUD. Engraftment, GVHD, CMV reactivations, relapse, survival outcomes, and complications were assessed using SPSS v25. A total of 48 patients (CNI/MTx: 35; PTCy: 13) were analysed. Baseline characteristics, including age, donor type, and diagnosis distribution, were comparable between groups. Acute GVHD occurred in 25.7% vs. 7.7% and chronic GVHD in 42.8% vs. 38.5% of patients, respectively. The mean RFS was 37.1 ± 4.6 vs. 26.1 ± 4.0 months, with median RFS not reached. The 12, 18, and 24 months RFS were 60.0%, 60.0%, and 60.0% for CNI/MTx and 72.5%, 60.4%, and 60.4% for PTCy. There was no significant difference. PTCy-based GVHD prophylaxis appears to be effective and well-tolerated in matched donor HSCT, with low rates of GVHD and transplant-related mortality. Further randomized trials comparing PTCy with CNI + MTx are needed to confirm these findings.